Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Emerging treatments and signaling pathway inhibitors.

Tang JY, Marghoob AA.

Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. doi: 10.1016/j.sder.2011.11.002. Review.

PMID:
22177102
2.

Oral hedgehog-pathway inhibitors for basal-cell carcinoma.

Lear JT.

N Engl J Med. 2012 Jun 7;366(23):2225-6. doi: 10.1056/NEJMe1202170. No abstract available.

PMID:
22670909
3.

Vismodegib in advanced basal-cell carcinoma.

Henkin RI.

N Engl J Med. 2012 Sep 6;367(10):970; author reply 970-1. doi: 10.1056/NEJMc1208003#SA2. No abstract available.

PMID:
22931271
4.

Harnessing hedgehog for the treatment of basal cell carcinoma.

Harms KL, Dlugosz AA.

JAMA Dermatol. 2013 May;149(5):607-8. doi: 10.1001/jamadermatol.2013.448. No abstract available.

PMID:
23677088
5.

Targeting the hedgehog pathway to treat basal cell carcinoma.

Geeraert P, Williams JS, Brownell I.

J Drugs Dermatol. 2013 May;12(5):519-23. Review.

PMID:
23652945
6.

Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.

Ali FR, Lear JT.

Br J Dermatol. 2013 Jul;169(1):53-7. doi: 10.1111/bjd.12311. Review.

PMID:
23488543
7.

Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma.

Tang JY.

Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S6-9. doi: 10.1016/j.sder.2011.11.001. Review.

PMID:
22177103
8.
9.

Hedgehog pathway inhibition and the race against tumor evolution.

Atwood SX, Chang AL, Oro AE.

J Cell Biol. 2012 Oct 15;199(2):193-7. doi: 10.1083/jcb.201207140.

10.

Hedgehog Pathway Inhibition.

Sekulic A, Von Hoff D.

Cell. 2016 Feb 25;164(5):831. doi: 10.1016/j.cell.2016.02.021.

11.

Basal cell carcinoma: hedgehog pathway inhibitors and beyond.

Walls B.

Cutis. 2013 Jun;91(6):E1-4. Review. No abstract available.

PMID:
23837158
12.

Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.

Mohan SV, Chang AL.

Semin Cutan Med Surg. 2014 Jun;33(2):68-71. Review.

PMID:
25085664
13.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr.

N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.

14.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
15.

[Inhibitors of the Hedgehog signalling pathway: hope for the treatment of basal cell carcinoma].

Vidal V.

Med Sci (Paris). 2010 Mar;26(3):231-3. doi: 10.1051/medsci/2010263231. French. No abstract available.

16.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
17.

Clinical experience with Hedgehog pathway inhibitors.

Low JA, de Sauvage FJ.

J Clin Oncol. 2010 Dec 20;28(36):5321-6. doi: 10.1200/JCO.2010.27.9943. Epub 2010 Nov 1.

PMID:
21041712
18.

Hedgehog signaling in basal cell carcinoma.

Otsuka A, Levesque MP, Dummer R, Kabashima K.

J Dermatol Sci. 2015 May;78(2):95-100. doi: 10.1016/j.jdermsci.2015.02.007. Epub 2015 Feb 23. Review.

PMID:
25766766
19.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
20.

Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE.

Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Epub 2015 Oct 5. Review.

PMID:
26437034

Supplemental Content

Support Center